B細胞性非ホジキンリンパ腫の世界市場 - 市場規模、動向、疫学、疾患管理、パイプライン分析、競合の評価、アンメットニーズ、臨床試験戦略、予測（2021年～2031年）

当レポートでは、世界のB細胞性非ホジキンリンパ腫市場について調査分析し、市場規模と動向、上市済み薬品とパイプライン薬品の分析、競合の評価などを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 疾患の概要

• 病因と疫学
• B細胞性非ホジキンリンパ腫の治療アルゴリズム

第4章 パイプライン薬品の概要

• パイプライン分析
• ターゲット分析と臨床ベンチマーク

第5章 市場の見通し

• 促進要因と障壁による10年間の市場の分析

第6章 アンメットニーズ

第7章 承認可能性分析とフェーズ移行成功率分析

第8章 競合の評価

• 競合分析：治療クラス別

第9章 将来の企業

• パイプラインの強度に基づく将来の企業

第10章 付録

第11章 連絡先

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) for marketed and pipeline therapies with established mechanisms of action by class, including early to late clinical stage pipeline products, with a launch date assessment by market for B-cell non-Hodgkin's lymphoma (NHL). This report also contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of B-cell NHL, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology. Additionally, the report evaluates indication-specific unmet needs and competitive assessments, and identifies key future players in the B-cell NHL therapy market.

Synopsis

• Cell therapies face a high level of competition in NHL. The first line of therapy is well served by combination therapies, particularly chemotherapy plus Rituxan/biosimilar rituximab, which induces durable remissions in a large subset of patients.
• The B-cell NHL pipeline is dominated by CAR-T cells. The success of CAR-Ts in NHL has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy (CGT) classes combined. Pipeline CAR-Ts will likely require a novel target, increased efficacy, lower price, or simplified manufacture to penetrate the crowded CAR-T market.
• The NHL CGT market is projected to reach $8.4 billion in 8MM peak sales.
• A high level of unmet need exists in certain patient populations, and could be addressed by CGT agents.

Key Highlights

• Report deliverables include a PowerPoint report and Excel-based forecast model
• Forecast includes 8 countries
• Forecast covers 2021-2031
• Seven markets are extrapolated, obtaining a 15-market value for all NHL therapeutics

Scope

• This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

OBTAIN CELL THERAPY SALES FORECASTS ACROSS MULTIPLE REGIONS

GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as -

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in eac h market?
• What is the total market value projected for the forecast end, in 2031?

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Report Scope

2. Executive Summary

3. Disease Overview

• 3.1. Etiology & Epidemiology
• 3.2. B-Cell NHL Treatment Algorithm

4. Pipeline Drugs Overview

• 4.1. Pipeline Analysis
• 4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

• 5.1. 10-Year Market Analysis with Drivers and Barriers

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

• 8.1. Competitive Analysis by Class of Therapy

9. Future Players

• 9.1. Future Players Based on Pipeline Strength

10. Appendix

• 10.1. Cell Therapies Forecast Methodology Overview
• 10.2. Pricing of Cell Therapies
• 10.3. Pipeline Launch Assumptions
• 10.4. Abbreviations
• 10.5. Methodology
• 10.6. About the Authors

11. Contact Us